Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials.

Kerbusch, Thomas; Li, Hanbin; Wada, Russell; Jauslin, Petra M; Wenning, Larissa

Kerbusch, Thomas; Li, Hanbin; Wada, Russell; Jauslin, Petra M; Wenning, Larissa.

Affiliation

Li H; Certara USA, Inc., Princeton, NJ, USA.
Wada R; Certara USA, Inc., Princeton, NJ, USA.
Jauslin PM; Certara USA, Inc., Princeton, NJ, USA.
Wenning L; Merck & Co., Inc., Kenilworth, NJ, USA.

Br J Clin Pharmacol ; 86(9): 1795-1806, 2020 09.

Article in En | MEDLINE | ID: mdl-32162721

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Psoriasis; Aged; Double-Blind Method; Humans; Pharmaceutical Preparations; Psoriasis/drug therapy; Severity of Illness Index; Treatment Outcome

Key words

dermatology; modelling and simulation; pharmacodynamics; pharmacokinetic-pharmacodynamic; psoriasis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Humans Language: En Journal: Br J Clin Pharmacol Year: 2020 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google